Prevention of Loperamide-Induced Constipation in Mice and Alteration of 5-Hydroxytryotamine Signaling by Ligilactobacillus salivarius Li01/Experiment 3

From BugSigDB


Reviewed Marked as Reviewed by KateRasheed on 2025-6-10

Curated date: 2025/05/02

Curator: Montana-D

Revision editor(s): Montana-D

Subjects

Location of subjects
China
Host species Species from which microbiome was sampled. Contact us to have more species added.
Mus musculus
Body site Anatomical site where microbial samples were extracted from according to the Uber Anatomy Ontology
Intestine secretion Intestinal juice,Intestinal secretion,Succus entericus,Intestine secretion,intestine secretion
Condition The experimental condition / phenotype studied according to the Experimental Factor Ontology
Treatment outcome measurement Treatment outcome measurement,treatment outcome measurement
Group 0 name Corresponds to the control (unexposed) group for case-control studies
LOP (Loperamide-induced constipation)
Group 1 name Corresponds to the case (exposed) group for case-control studies
Li01 (Ligilactobacillus salivarius treatment)
Group 1 definition Diagnostic criteria applied to define the specific condition / phenotype represented in the case (exposed) group
Mice that received a daily gavage of 0.4 mL Li01 solution (~10^10 CFU/mL) for 15 days and 0.2 mL loperamide hydrochloride (10 mg/kg body weight) from the 8th to 15th day to induce constipation.
Group 0 sample size Number of subjects in the control (unexposed) group
6
Group 1 sample size Number of subjects in the case (exposed) group
6

Lab analysis

Sequencing type
16S
16S variable region One or more hypervariable region(s) of the bacterial 16S gene
V3-V4
Sequencing platform Manufacturer and experimental platform used for quantifying microbial abundance
Illumina

Statistical Analysis

Data transformation Data transformation applied to microbial abundance measurements prior to differential abundance testing (if any).
relative abundances
Statistical test
ANOVA
Kruskall-Wallis
Significance threshold p-value or FDR threshold used for differential abundance testing (if any)
0.05
MHT correction Have statistical tests be corrected for multiple hypothesis testing (MHT)?
No


Signature 1

Reviewed Marked as Reviewed by KateRasheed on 2025-6-10

Curated date: 2025/05/02

Curator: Montana-D

Revision editor(s): Montana-D

Source: Figure 5E

Description: Differentially abundant taxon between the LOP (Loperamide-induced) group and Li01 (Ligilactobacillus salivarius) group.

Abundance in Group 1: increased abundance in Li01 (Ligilactobacillus salivarius treatment)

NCBI Quality ControlLinks
Rikenellaceae_RC9Rikenellaceae_RC9

Revision editor(s): Montana-D